Edition:
United States

Valeant Pharmaceuticals International Inc (VRX.N)

VRX.N on New York Stock Exchange

9.25USD
28 Apr 2017
Change (% chg)

$-0.13 (-1.39%)
Prev Close
$9.38
Open
$9.39
Day's High
$9.49
Day's Low
$9.20
Volume
2,327,182
Avg. Vol
3,071,971
52-wk High
$38.48
52-wk Low
$8.32

Latest Key Developments (Source: Significant Developments)

Bausch + Lomb gets 510(K) FDA clearance for vitesse
Wednesday, 26 Apr 2017 07:30am EDT 

April 26 (Reuters) - Valeant Pharmaceuticals International Inc :Bausch + Lomb receives 510(K) clearance from FDA for vitesse, the first and only hypersonic, open-port vitrectomy system.  Full Article

Valeant announces pricing for Siliq
Friday, 21 Apr 2017 07:30am EDT 

April 21 (Reuters) - Valeant Pharmaceuticals International Inc :Valeant's patient access and pricing committee announces pricing for Siliq(brodalumab) as the lowest priced injectable biologic for moderate-to-severe plaque psoriasis.Valeant - sales and marketing of Siliq are expected to commence in U.S. During second half of 2017.Valeant - decided to list Siliq injection, at $3,500 per month.Valeant - Siliq will also be included in company's patient access program to further offer financial support and access to patients.  Full Article

Bausch + lomb receives 510(k) clearance from FDA for stellaris elite next-generation phacoemulsification platform
Thursday, 6 Apr 2017 07:30am EDT 

Valeant Pharmaceuticals International Inc : Bausch + lomb receives 510(k) clearance from fda for stellaris elite™ next-generation phacoemulsification platform . Bausch + lomb receives 510(k) clearance from fda for stellaris elite™ next-generation phacoemulsification platform . Valeant - bausch + lomb plans to launch retina applications for stellaris elite this summer .Valeant - retina applications for stellaris elite will integrate both retina and cataract capabilities into a single machine.  Full Article

Bausch + Lomb Canada launches bepreve 1.5 pct w/v for allergic conjunctivitis
Wednesday, 22 Mar 2017 07:30am EDT 

Valeant Pharmaceuticals International Inc :Bausch + Lomb - Bausch + Lomb Canada launches bepreve (bepotastine besilate ophthalmic solution) 1.5 pct w/v for allergic conjunctivitis.  Full Article

Bausch + Lomb and Nicox announce PDUFA date for novel glaucoma candidate latanoprostene bunod
Monday, 20 Mar 2017 05:00pm EDT 

Nicox Sa : Bausch + lomb and nicox announce pdufa date for novel glaucoma candidate latanoprostene bunod .Valeant - fda has set a pdufa date of august 24, 2017 for its decision on new drug application (nda) for latanoprostene bunod ophthalmic solution.  Full Article

ValuAct reports open market purchse of 500,000 shares of Valeant Pharma
Thursday, 16 Mar 2017 05:47pm EDT 

Valeant Pharmaceuticals International Inc : ValueAct Holdings LP reports open market purchse of 500,000 shares of valeant pharmaceuticals at average price of $10.88/share on March 14 - SEC filing .ValueAct Holdings LP reports open market purchse of 2.5 million shares of Valeant Pharmaceuticals at average price of $10.81/share on March 14.  Full Article

Valueact Holdings reports 5.2 pct stake in Valeant Pharma
Thursday, 16 Mar 2017 05:29pm EDT 

Valeant Pharmaceuticals International Inc : Valueact Holdings L.P. Reports 5.2 percent stake in valeant pharma, as of march 14, 2017 . Valueact Holdings-have had, intend to continue to have discussions with officers & directors of valeant to discuss ways to "enhance shareholder value" . Valueact Holdings l.p. Acquired securities of valeant based on belief that securities were "undervalued", represented "attractive investment opportunity" . Valueact Holdings says topics of conversations with valeant will include management, board composition, operations, capital allocation, among others .Valueact Holdings says topics of conversations with valeant will also include financial condition, mergers and acquisitions strategy, overall business strategy.  Full Article

Valeant Pharma CFO Paul Herendeen reports open market purchase of co's shares
Thursday, 16 Mar 2017 05:13pm EDT 

Valeant Pharmaceuticals International Inc :Valeant pharmaceuticals-cfo paul herendeen reports open market purchase of 24,000 shares of co's common stock at average price of $10.72per share on march 14.  Full Article

Valeant's Bausch + Lomb reports introduction of Biotrue Oneday
Wednesday, 15 Mar 2017 07:00am EDT 

Valeant Pharmaceuticals International Inc :Valeant - subsidiary Bausch + Lomb, announced introduction of Biotrue Oneday for astigmatism daily disposable contact lenses.  Full Article

Pershing Square Capital Management says in regulatory filing it dissolved stake in Valeant as of March 13, 2017
Tuesday, 14 Mar 2017 04:36pm EDT 

Pershing Square Capital Management LP:Pershing Square Capital Management LP says in regulatory filing it dissolved stake in Valeant Pharma as of March 13, 2017.  Full Article

More From Around the Web

Photo

Valeant prices psoriasis treatment at $3,500 per month (April 21)

(In April 21 story, corrects paragraph 5 to say Taltz's list price is $4,469 per month. Removes reference of pricing from analyst)